Dublin, Oct. 18, 2022 (GLOBE NEWSWIRE) -- The "Contrast Media - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
Global Contrast Media Market to Reach $5.4 Billion by 2026
Contrast agents help in advanced visualization of biological structures; and helps capture hard-to-image anatomical regions. They help eliminate errors caused by radiologist`s perception which tends to influence interpretation of the true structure of the underlying anatomy. Oral, intravenous, rectal, and intrathecal contrast agents are indispensable today in the practice of radiology for their most primary benefit which is enhanced visibility of internal structures.
Efficiency of contrast media over the years has evolved from high-osmolar contrast media (HOCM) which have limited utility and higher side-effects to low-osmolality contrast agents which are safer and preferred for pediatric patients. Amid the COVID-19 crisis, the global market for Contrast Media estimated at US$4.8 Billion in the year 2022, is projected to reach a revised size of US$5.4 Billion by 2026, registering a compounded annual growth rate (CAGR) of 2.9% over the period.
The United States represents the largest regional market for Contrast Media and is projected to reach US$2.1 Billion by 2026. China is expected to spearhead growth and emerge as the fastest growing regional market with a CAGR of 4.3% over the period.
Growth in the global market is set to be driven by prevalence of chronic diseases among the growing global population, aging population, and rise of nuclear medicine. There is strong demand for radioactive contrast agents, also known as radioactive agent, radioactive dye or radiopharmaceutical. Demand is hugely supported by the rise of nuclear medicine. These radioactive materials help diagnose and treat a wide variety of diseases and disorders.
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Migration to Value Based Care Throws the Focus on Quality & Value of Imaging & Its Ability to Improve Patient Care by Providing Better Quality Images
- With "Value" being the new Currency in Healthcare Markets Worldwide, Value Based Imaging Will Positively Impact Contrast Enhanced Imaging Procedures
- Growing Preference for Non-Ionizing Radiation-Based Radioimaging Drives Demand for Contrast Enhanced MRI
- Commercially Available MRI Contrast Agents
- Spurred by Safety & Efficiency Benefits, Growing MRI Procedures & Parallel Increase in MRI Machines to Benefit Demand for MRI Contrast Agents
- Evolving Clinical Applications of Contrast-Enhanced Ultrasound (CEUS) Drive Demand for Ultrasound Contrast Agents
- Clinically Available Ultrasound Contrast Agents
- Growing Use of CEUS in Emergency and Critical Care
- Special Focus on Microbubble Contrast Agents for Ultrasound Imaging
- Clinical Applications of Microbubbles
- Oscillating Microbubbles: To Revolutionize Ultrasound
- Growing Market for Ultrasound Equipment Pushes Up the Number of CEUS Procedures Performed
- Continued Value of CT Imaging in Cardiology Despite Risk of Radiation Exposure Drives Demand for Contrast-Enhanced CT
- Contrast Agents Used in CT Imaging by Class: A Snapshot
- CCTA Gaining Traction in Coronary Arteries Imaging
- List of Iodine-Containing Contrast Agents for Coronary CT Angiography
- Growing Access to CT Imaging Bodes Well for CT Contrast Agents
- Rise in Image Guided Surgeries Drives Demand for Contrast Agents
- Emergence of Molecular-Targeted Fluorescent Tracers
- Select Potential "always-on" Targeted Tracers for Fluorescence Image-Guided Surgery (FIGS)
- The Use of Gold Nanoclusters as Contrast Agent for IGS of Head and Neck Tumors
- Better Surgical Outcome Drives the Number of Image Guided Surgeries Performed Worldwide Along with Demand for Contrast Agents
- Stringent Guidelines & Implementation of Best Practices for Safe Use of Contrast Agents to Encourage Patient Acceptance of Contrast Enhanced Imaging
- Safety Issues with Iodinated Agents, Gadolinium BCA and Microbubbles
- Symptoms of Reaction to Administration of Iodinated Contrast Media Agents
- Innovations Remain Crucial to Growth
- A Review of Advancements in Contrast Media Injector Technology
- Development of New Contrast Agents
- Key Challenges Confront the Market
- Advances in Imaging Technology Reduce Contrast Media Use
- Product Recalls and Side Effects of Contrast Media Challenge Growth
- A Snapshot of Side Effects, Allergic and Adverse Reactions with Contrast Agents
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
IV. COMPETITION
Companies Mentioned
- AMAG Pharmaceuticals, Inc.
- Bayer AG
- Daiichi Sankyo Co., Ltd.
- GE Healthcare
- Guerbet Group
- Starpharma Holdings Limited
For more information about this report visit https://www.researchandmarkets.com/r/u6su6s
